Form 8-K - Current report:
SEC Accession No. 0001558370-25-004154
Filing Date
2025-03-31
Accepted
2025-03-31 16:10:12
Documents
16
Period of Report
2025-03-31
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K fbio-20250331x8k.htm   iXBRL 8-K 38986
2 EX-99.1 fbio-20250331xex99d1.htm EX-99.1 287289
3 GRAPHIC fbio-20250331xex99d1001.jpg GRAPHIC 12073
  Complete submission text file 0001558370-25-004154.txt   521681

Data Files

Seq Description Document Type Size
4 EX-101.SCH fbio-20250331.xsd EX-101.SCH 4555
5 EX-101.DEF fbio-20250331_def.xml EX-101.DEF 14890
6 EX-101.LAB fbio-20250331_lab.xml EX-101.LAB 17165
7 EX-101.PRE fbio-20250331_pre.xml EX-101.PRE 14855
18 EXTRACTED XBRL INSTANCE DOCUMENT fbio-20250331x8k_htm.xml XML 7218
Mailing Address 1111 KANE CONCOURSE SUITE 301 BAY HARBOR ISLANDS FL 33154
Business Address 1111 KANE CONCOURSE SUITE 301 BAY HARBOR ISLANDS FL 33154 781-652-4500
Fortress Biotech, Inc. (Filer) CIK: 0001429260 (see all company filings)

EIN.: 205157386 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35366 | Film No.: 25793278
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)